Archive: July 2023
Highlights in Lung Cancer
Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer The use of osimertinib (Tagrisso, AstraZeneca) after surgery improves overall survival (OS) in patients with early-stage, EGFR-mutated […]
Highlights in Leukemia and Lymphoma
Nivolumab Outperforms Brentuximab Vedotin in Newly Diagnosed Advanced Hodgkin Lymphoma Nivolumab (Opdivo, Bristol Myers Squibb) plus doxorubicin, vinblastine, and dacarbazine (AVD) significantly improved progression-free survival (PFS) […]
Highlights in Gynecologic Cancer
Simple Hysterectomy Noninferior to Radical Hysterectomy in Low-Risk, Early-Stage Cervical Cancer Simple hysterectomy is noninferior to radical hysterectomy in reducing the 3-year pelvic recurrence rate among […]
Highlights in Genitourinary Cancer
Erdafitinib Improves Overall Survival vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma Erdafitinib (Balversa, Janssen) significantly improves overall survival (OS) compared with chemotherapy in patients with FGFR-altered […]
Highlights in Colorectal Cancer
Neoadjuvant Chemotherapy Allows Most Patients With Locally Advanced Rectal Cancer to Skip Pelvic Chemoradiation The phase 3 PROSPECT trial found that the addition of neoadjuvant chemotherapy […]
Highlights in Breast Cancer
Addition of Ribociclib to Endocrine Therapy Improves Outcomes in Early-Stage, HR+/HER2– Breast Cancer The addition of ribociclib (Kisqali, Novartis) to endocrine therapy improves invasive disease–free survival […]